Donor/recipient Rh-mismatched allogeneic hematopoietic stem cell transplantation: transfusion strategy and allo-immunization to red blood cell antigens.
Journal
Bone marrow transplantation
ISSN: 1476-5365
Titre abrégé: Bone Marrow Transplant
Pays: England
ID NLM: 8702459
Informations de publication
Date de publication:
25 May 2024
25 May 2024
Historique:
received:
20
02
2024
accepted:
16
05
2024
revised:
13
05
2024
medline:
26
5
2024
pubmed:
26
5
2024
entrez:
25
5
2024
Statut:
aheadofprint
Résumé
In the case of donor/recipient rhesus (Rh)-incompatibility after allogeneic hematopoietic stem cell transplantation (alloHSCT), the transfusion policy in France is to transfuse red blood cells (RBC) in the donor's Rh phenotype from the day of transplantation, leading to a risk of allo-immunization, either of donor or recipient origin. In this single-center retrospective study, the incidence of donor/recipient Rh incompatibility was 7.1% over an 8-year period including 1012 alloHSCT. Six of 58 evaluable patients (10.3%) developed alloantibodies to RBC antigens within one year of alloHSCT. None of these allo-immunizations were directed against the donor-mismatched Rh antigens and none could have been prevented by the transfusion of recipient and donor Rh-compatible RBC units. None of these allo-immunizations led to immune-mediated hemolytic anemia. We observed a statistically significant higher incidence of chronic GVHD among patients with anti-RBC allo-immunization. In the context of donor/recipient Rh incompatibility, the transfusion of packed RBC units in the donor's Rh phenotype from the day of alloHSCT is feasible and not associated with a high risk of allo-immunization. The generalization of this strategy could be discussed even when donor and recipient Rh phenotypes could be respected, to allow the preservation of units of infrequent phenotypes for other indications.
Identifiants
pubmed: 38796632
doi: 10.1038/s41409-024-02316-0
pii: 10.1038/s41409-024-02316-0
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Nature Limited.
Références
Rowley SD, Donato ML, Bhattacharyya P. Red blood cell-incompatible allogeneic hematopoietic progenitor cell transplantation. Bone Marrow Transplant. 2011;46:1167–85.
doi: 10.1038/bmt.2011.135
pubmed: 21897398
Holbro A, Passweg JR. Management of hemolytic anemia following allogeneic stem cell transplantation. Hematol Am Soc Hematol Educ Progr. 2015;2015:378–84.
doi: 10.1182/asheducation-2015.1.378
Yousuf R, Thalith NFA, Loong TY, Leong CF. Naturally occurring ‘enzyme only’ anti-E antibody: a rare occurrence. Bangladesh J Med Sci. 2019;18:818–9.
doi: 10.3329/bjms.v18i4.42911
Harrison J. The ‘naturally occurring’ anti‐E. Vox Sang. 1970;19:123–31.
pubmed: 4992289
Young PP, Goodnough LT, Westervelt P, Diersio JF. Immune hemolysis involving non-ABO/RhD alloantibodies following hematopoietic stem cell transplantation. Bone Marrow Transplant. 2001;27:1305–10.
doi: 10.1038/sj.bmt.1703074
pubmed: 11548850
Franchini M, Gandini G, Aprili G. Non-ABO red blood cell alloantibodies following allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2004;33:1169–72.
doi: 10.1038/sj.bmt.1704524
pubmed: 15094753
Blin N, Traineau R, Houssin S, Peffault de Latour R, Petropoulou A, Robin M, et al. Impact of donor-recipient major ABO mismatch on allogeneic transplantation outcome according to stem cell source. Biol Blood Marrow Transplant. 2010;16:1315–23.
doi: 10.1016/j.bbmt.2010.03.021
pubmed: 20353831
Giraud C, Thibert JB, Desbrosses Y, Debiol B, Alsuliman T, Bardiaux L, et al. Transfusion dans l’autogreffe et l’allogreffe de cellules souches hématopoïétiques chez l’adulte et l’enfant: recommandations de la Société francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC). Bull du Cancer. 2019;106:S52–8.
doi: 10.1016/j.bulcan.2018.08.016
Worel N, Böhm A, Rabitsch W, Leitner G, Mitterbauer M, Kalhs P, et al. Frequency and prognostic value of D alloantibodies after D-mismatched allogeneic hematopoietic stem cell transplantation after reduced-intensity conditioning. Transfusion. 2012;52:1348–53.
doi: 10.1111/j.1537-2995.2011.03457.x
pubmed: 22128859
Chan JYS, Tokessy M, Saidenberg E, Giulivi A, Tay J, Allan DS. Rh D alloimmunization in allogeneic HSCT. Bone Marrow Transplant. 2013;48:459–60.
doi: 10.1038/bmt.2012.152
pubmed: 22890290
Xhaard A, Bouton M, Delugin L, Giraud C, Guyon A, Giroux-Lathuile C, et al. [Transfusion management and immuno-hematological follow-up after allogeneic hematopoietic cell transplantation: recommendations of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)]. Bull du Cancer. 2024;11;S78–83.
Bailén R, Kwon M, Pérez-Corral AM, Pascual C, Buño I, Balsalobre P, et al. Transient hemolysis due to anti-D and anti-A1 produced by engrafted donor’s lymphocytes after allogeneic unmanipulated haploidentical hematopoietic stem cell transplantation. Transfusion. 2017;57:2355–8.
doi: 10.1111/trf.14232
pubmed: 28703860
Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant. 2009;15:1628–33.
doi: 10.1016/j.bbmt.2009.07.004
pubmed: 19896087
pmcid: 2861656
Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant. 1995;15:825–8.
pubmed: 7581076
Jagasia MH, Greinix HT, Arora M, Williams KM, Wolff D, Cowen EW, et al. National Institutes of Health Consensus Development Project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant. 2015;21:389–401.e1.
doi: 10.1016/j.bbmt.2014.12.001
pubmed: 25529383
Lin Y, Saskin A, Wells RA, Lenis M, Mamedov A, Callum J, et al. Prophylactic RhCE and Kell antigen matching: impact on alloimmunization in transfusion-dependent patients with myelodysplastic syndromes. Vox Sang. 2017;112:79–86.
doi: 10.1111/vox.12455
pubmed: 28097704
Gupta P, LeRoy SC, Luikart SD, Bateman A, Morrison VA. Long-term blood product transfusion support for patients with myelodysplastic syndromes (MDS): cost analysis and complications. Leuk Res. 1999;23:953–9.
doi: 10.1016/S0145-2126(99)00113-7
pubmed: 10573142
Sanz C, Nomdedeu M, Belkaid M, Martinez I, Nomdedeu B, Pereira A. Red blood cell alloimmunization in transfused patients with myelodysplastic syndrome or chronic myelomonocytic leukemia. Transfusion. 2013;53:710–5.
doi: 10.1111/j.1537-2995.2012.03819.x
pubmed: 22845746
Ortiz S, Orero MT, Javier K, Villegas C, Luna I, Pérez P, et al. Impact of azacitidine on red blood cell alloimmunisation in myelodysplastic syndrome. Blood Transfus. 2017;15:472–7.
pubmed: 27416573
pmcid: 5589710
Schonewille H, Haak HL, van Zijl AM. Alloimmunization after blood transfusion in patients with hematologic and oncologic diseases. Transfusion. 1999;39:763–71.
doi: 10.1046/j.1537-2995.1999.39070763.x
pubmed: 10413286
Xhaard A, Miekoutima E, Pirenne F, François A, Tiberghien P, Sebert M, et al. The transfusion of non-prophylactically RH-KEL1 antigen-matched red blood cells is feasible in selected myelodysplastic syndrome and acute myeloid leukaemia patients. Vox Sang. 2022;117:693–700.
doi: 10.1111/vox.13237
pubmed: 34985763
Mielcarek M, Zaucha JM, Sandmaier B, Maloney D, Butrynski J, Maris M, et al. Type of post-grafting immunosuppression after non-myeloablative blood cell transplantation may influence risk of delayed haemolysis due to minor ABO incompatibility. Br J Haematol. 2002;116:500–1.
doi: 10.1046/j.1365-2141.2002.03268.x
pubmed: 11841459
Miklos DB, Kim HT, Miller KH, Guo L, Zorn E, Lee SJ, et al. Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission. Blood. 2005;105:2973–8.
doi: 10.1182/blood-2004-09-3660
pubmed: 15613541